anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A therapeutic exercise program for treating a patient whose abnormal condition, regardless of its nature and origin, is indicated by a resting heart pulse rate that deviates from the normal resting rate and a maximum heart pulse rate obtainable by physical exertion that deviates from the normal maximum rate, i.e., compromised range and flexibility. At the outset of the program, the patient is tested to determine his initial heart pulse range extending between his resting and maximum heart pulse rates to provide a base line for the program. In the course of the program, the patient whose heart beat is continuously monitored while exercising, undergoes a series of exercise-relaxation cycles. During each cycle, the exercising patient expends a surge of energy giving rise to a high pulse peak rate, the patient then relaxing to complete the cycle. This energy surge induces in the patient&#39;s heart a pendulum effect, causing the pulse rate to swing down from the peak rate to a resting rate below that in the initial range. The temporal conditions under which the program is conducted and its duration are such as to bring about a progressive rise in the maximum pulse rate attainable by the patient and to expand his range and increase the flexibility whereby at the conclusion of the program, the patient&#39;s maximum heart pulse rate and resting pulse rate approach those of an individual free of the abnormal condition.
A system that automates and optimizes the workflows and transportation routes of one or more mobile medical units is provided. The mobile medical units may include mobile phlebotomy units for the onsite collection of medical specimens (e.g., blood). The system may include a plurality of mobile medical units (e.g., medically equipped vans) within a particular city, and a system for receiving and assigning medical workorders to particular mobile units (e.g., based on the mobile unit&#39;s location compared to that of the patient, availability, and other criteria). The system also may determine an optimized route to the patient for the mobile unit to follow and may provide additional administrative support to the mobile unit during the entire workflow process. The system also may perform onsite diagnostic tests on medical specimens collected from a patient (e.g., using medical test equipment), may flag abnormal test results, and may communicate the results to a healthcare provider. The system also may effect a particular treatment or prophylaxis for a disease or medical condition of a patient as indicated by the diagnostic test results acquired by a mobile medical unit at the patient&#39;s remote location.
PURPOSE:A remedy for angiocephalalgia, having a delayed effect, and a remedy for a hangover, containing gamma-amino acid or its derivative as a main active ingredient. CONSTITUTION:gamma-Aminobutyric acid, or its alpha-, or beta-substituted derivative is used as a remedy for angiocepthalalgia and a remedy for a hangover. gamma-Aminobutyric acid or its derivative is found to be effective only against angiocephalalgia among headaches of many causes. Its effect is in the order of alpha-Cl-gamma-aminobutyric acid&gt;gamma-aminobutyric acid&gt;beta-OH-gamma-aminobutyric acid. Its action is not immediate effect, and oral administration of 3g/day gamma-aminobutyric acid is required to keep for &gt;=3 days. When it is blended with aspirin or caffeine, it is provided with an immediate effect, and each effective dose of the components can be reduced. Consequently, the blend contributes to reduction in side effects of aspirin and caffeine.
PROBLEM TO BE SOLVED: To treat only required information while grasping the whole configuration of medical examination information when a large quantity of preserved medical card information is displayed in an electronic medical card system. SOLUTION: A binder where first hierarchy in medical information is defined is stored in a database. Tree structure is constituted in a client based on the binder and display is executed in a window 10. In display, an item having hierarchy below is called node and expressed by mark of &#39;+&#39; inside a square frame. It is changed into the mark of &#39;-&#39; at the time of extension like the item of a patient attribute. The item where actual data is displayed without having hierarchy below is called leaf and indicated by an icon where documents are made into a design. The node extended in this way is displayed by being inserted into the tree configuration of an extension source so that a user grasps the whole image of information while viewing required information.
Disclose and be used for the system and method for assisting emergency medical dispatcher to respond to urgent call. Computer implemented intervention schedule scheme is provided, and it comprises inquiry, generates suitable response for dispatcher enquiry call person. Provide and be used for auxiliary dispatching person and determine that patient suffers from the diagnostic tool of meningitic possibility. The information of the observation to patient about caller that this diagnostic tool is pass on based on caller, determines that patient suffers from meningitic possibility. This diagnostic tool can automatically be started or be manually booted as required by dispatcher by intervention schedule scheme. This diagnostic tool presents user interface, and it can provide for instructing caller to identify that patient suffers from the problem of meningitic S&amp;S and the input module that is associated with described problem etc.
The present invention relates to novel bladder related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as &#34;bladder antigens&#34;, and antibodies that immunospecifically bind these polypeptides, and the use of such bladder polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the bladder system, including, but not limited to, the presence of bladder cancer and bladder metastases. More specifically, isolated bladder nucleic acid molecules are provided encoding novel bladder polypeptides. Novel bladder polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human bladder polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the bladder, including bladder cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention.  The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.
Luminescent orthodontic appliances, such as brackets, archwires, bands and the like, having a luminescent pigment or mixture of luminescent pigments are described. In a preferred form, the luminescent pigment is a phosphorescent pigment comprising zinc sulfide doped with copper. The pigment gives the appliance a natural appearance in daylight and causes it to emit a greenish-white light in the dark after having been energized by an excitation light source. If desired, the luminescent orthodontic appliance may be made with a fluorescent pigment or a combination of fluorescent and phosphorescent pigments. If a fluorescent pigment is used, the bracket will exhibit a luminescence in daylight; whereas if a mixture of fluorescent and phosphorescent pigments are used, the appliance will luminesce in the dark after having been exposed to a light source, in addition to exhibiting a luminescence in the daylight. The luminescent appliances of this invention provide a fun alternative to traditional orthodontic appliances, particularly for younger patients, who can &#34;show off&#34; their braces to their families and friends.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide immune regulation based on the targeting of early activation molecules.  &lt;P&gt;SOLUTION: Methods are provided for treating subjects having disorders or conditions characterized by an unwanted immune response. The disorders can be characterized by a &#34;normal&#34; response or by an immunological response which increases as compared with what is usually observed in a subject. Examples of such a disorder are as indicated on the specification, and include an acute or chronic inflammatory disorder and an immunity disorder, for example an autoimmune disorder. The methods include administering an effective amount of at least one early activation molecule agonist to the subject.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention comprises compounds of the general formula: Ar1.CH:C(CN).CH2Z1 wherein Ar1 has 6 to 15 carbon atoms and is a phenyl group optionally substituted by an alkoxy group and/or a halogen atom or by the residue CH:CH.CH:CH- and Z1 is an alkoxy group; the preparation of a substance consisting of one or more nitriles of the formulae: &lt;FORM:0957797/C2/1&gt; &lt;FORM:0957797/C2/2&gt; wherein Ar is a phenyl group optionally substituted by an alkoxy, alkyl, amino, dialkylamino, group and/or a halogen atom or with a -CH:CH.CH:CH. residue and Z is an electrophilic group, by condensing an aldehyde Ar.CHO in the presence of a strong base with a b -substituted propionitrile Y.CH2CH2CN where Y is an electrophilic group, the group Z being the group Y or an alkoxy group derived from a solvent alcohol; and the preparation of a 2,4-diamino-5-arylmethylpyrimidine of the formula: &lt;FORM:0957797/C2/3&gt; by reacting a substance consisting of one or more nitriles Ia and Ib, prepared by the process above, with guanidine. Suitable electrophilic groups (Y) are ether, thioether and tertiary amino groups. The reaction to prepare the pyrimidines may be carried through in one stage.  The b -alkoxypropionitrile may be prepared in situ from acrylonitrile and the solvent alcohol. Specifications 687,032, 734,801, 875,562, 920,412, U.S.A. Specifications 2,579,259, 2,624,732, 2,658,897, 2,823,160 and 2,909,522 are referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a food composition achieving improvement of rough dry skin and increase of skin moisture.  &lt;P&gt;SOLUTION: This food composition contains α-linolenic acid, and a glycosphingolipid or a mucopolysaccharide. The α-linolenic acid is the one contained in Japanese basil oil, perilla oil or linseed oil. The glycosphingolipid comprises the one extracted from rice, wheat, potatoes, or the like. The mucopolysaccharide comprises hyaluronic acid, chondroitin or glucosamine, or alternatively a mixture thereof.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Methods of improving the stability of a non-petroleum oil using cannabinoid compounds are described herein. The cannabinoid compounds can include cannabigerol (&#34;CBG&#34;) and/or cannabigerolic acid (&#34;CBGA&#34;). The cannabinoid compounds can be antioxidants. Non-petroleum oils can suffer from short lifespans due to stability issues caused by oxidative damage from exposure to light, heat, and oxygen. It has presently been discovered that the oxidative stability of non-petroleum oils can be improved through the inclusion of one or more cannabinoid compounds. Compositions and articles including the cannabinoid compounds are further disclosed.
FIELD: medicine, allergology. SUBSTANCE: invention relates to method of preparing allergens in aim of their following using for detection of allergic response of patient in professional trail selection. Method involves the development of preparing industrial allergen by extraction of air pollutants in industrial compartment. Taking away air is passed successively through two Bobrov&#39;s devices containing 70% ethyl alcohol. Mixture is shaken, centrifuged, dried and obtained precipitated is defatted with, for example, ether followed by dilution of allergen with standard dilution liquid. EFFECT: expanded assortment of measures for control of allergic diseases. 3 cl, 1 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for detection in which a regulatory sequence can be identified among other screenings in relation to systematic elucidation and identification of the regulatory sequence.  &lt;P&gt;SOLUTION: There is provided a method for detecting a DNA sequence having characteristics of regulating gene transcription, and optionally selecting thereof. The method includes preparing a vector comprising various fragments in a transcription system. The vector includes: (i) an element having characteristics of suppressing the gene transcription; and (ii) a promoter directing the transcription of a reporter gene. Furthermore, there is provided a method for use thereof in various fields such as, but not limited to protein production, diagnostics, transgenic plants and animals, and the therapeutic field by the method.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The embodiments herein provide a portable health care tele-monitoring device for intensive care unit of hospital, inside ambulance/vehicle or home. The device facilitates real time monitoring of patient&#39;s health. Patient information gathered using the device comprises personal details, health records and real time medical parameters of the patient. A blood parameter measurement device, external devices and vital sign devices are connected to the device using various ports and connectors provided in the device. The device facilitates transmission of patient information to a central location such as hospital, personal clinic of a doctor or health care centre and receiving medical prescription remotely over communication network from doctor/medical expert based on patient information captured by the device. Optionally physical copy of vital signs and blood parameters is printed using the device. A user interface is provided to enable patient/user for communicating with doctor/medical expert whenever needed.
The invention belongs to the technical field of treating tumor by immunization therapy, in particular to a method for treating intestinal cancer and pancreatic cancer cells by methionine enkephalin under conditions of in-vivo injection and in-vitro cell culture so as to achieve the treating aim. The methionine enkephalin is prepared into injection according to 0.0001 to 10 milligram/milliliter or carries out stimulus under the condition of cell culture of in-vitro T lymphocyte. After the concentration range of the methionine enkephalin is between 10&lt;-2&gt; and 10&lt;-16&gt; gram molecule/liter, the methionine enkephalin is fed back to internal, or is directly injected through vein, hypodermic and muscle. The method is characterized in that the methionine enkephalin directly acts on immune system cells or cancer cells in-vivo or in-vitro under culture condition with small dosage and high efficiency. The immune system cells activated by the methionine enkephalin have higher efficient of immunological cell proliferation number and cytoactive than those activated by the prior method, generally 5 to 10 times higher than the prior method, particularly the number of the T lymphocyte is significantly increased. The methionine enkephalin directly kills intestinal cancer and pancreatic cancer cells through receptor binding.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide new antimicrobial polypeptides and methods of use.  &lt;P&gt;SOLUTION: There are disclosed compositions of substances comprising a purified lantibiotic mutacin 1140 which substantially comprises no bacterial host. There are disclosed antimicrobial compounds, their compositions and their use including treatment and prevention of bacterial infectious diseases. The compounds and compositions comprise lantibiotic polypeptides and nucleic acid sequences encoding the polypeptides. The compounds and compositions are useful as antimicrobials in antibiotic pharmaceutical preparations and as an antimicrobial or antiseptic dentifrice.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To provide the titled contrasting agent introducible into a lymphatic system without using celiotomic operation and useful in the medical field, by suing fine particles of a substance having a radiolucency different from human body and dispersing the particles in a liquid. CONSTITUTION:Fine particles of a substance having a radiolucency different from human body (e.g. silver particles, metallic iodine, barium sulfate, polymeric substance, etc.) are dispersed in a liquid (a liquid having low viscosity, e.g. water, physiological saline water, Ringer&#39;s solution, etc.) and the dispersion is used as the objective contrasting agent for lymphatic system. The diameter of the fine particle is usually &lt;=40mu. The obtained contrasting agent has lymph- orienting property in itself, migrates automatically into the peripheral lymph by the injection into the celom to be contrasted and is taken into the lymphatic system. Accordingly, contrasting of the lymphatic system can be carried out without using surgical operation.
PURPOSE:To provide a medicinal agent having large intestine cancer-preventive effect along with having blood cholesterol-reducing activity, containing, as active ingredient, a partial hydrolyzate of glucomannan with a specific molecular weight range derived from devil&#39;s tongue. CONSTITUTION:Using, as starting material (s), devil&#39;s tongue powder, the glucomannan separated therefrom, or devil&#39;s tongue powder decolored and deodorized with an alcohol, the material (s) are partially hydrolyzed through acid hydrolysis or enzymolysis to produce a partial hydrolyzate 2000-5000 in average molecular weight. The objective medicinal agent contains this partial hydrolyzate as active ingredient. The above partial hydrolysis is pref. enzymolysis in terms of regulating the degree of decomposition, and it is desirable to use an endo-type enzyme capable of hydrolyzing the intramolecular beta-glucoside linkage of the glucomannan, esp. a cellulase derived from microorganisms belonging to Aspergillus.
A system for identifying and selecting a clinical trial, suitable for a specific patient, from a database. Initially, a database of clinical studies, such as the clinicaltrials.gov database, is searched to find the trials specific to a particular disease. All of the clinical trials in the disease-specific area are then extracted from the database. Next, all of the ‘exclusionary criteria’ listed in each trial are then identified and extracted. After identifying all of the criteria cumulatively across all of the clinical trials, a list is made of the criteria having the most redundancy, i.e., the criteria that are common to a predetermined number of the trials. The criteria is then ‘normalized’, or standardized, by assigning a single, consistent category for generating questions that can be answered by either “yes/no”, or selecting one of a small number of predetermined ranges. Finally, the number of criteria is reduced by eliminating the least exclusionary criteria. This reduction of redundant criteria allows the present system to thereafter generate a minimal list of questions that exclude the greatest number of trials for which a patient&#39;s medical condition does not qualify him or her. In operation, the patient or the patient&#39;s physician answers a set of questions using the information from the patient&#39;s medical record. In most cases, the present search engine generates the desired results of approximately 5 to 10 applicable clinical trials.
PROBLEM TO BE SOLVED: To obtain a plaster stably containing a medicine in high concentration, having high percutaneous absorption effect, reduced in peeling force in peeling and further having good handleability in attachment and feeling to uses during attachment and in peeling. SOLUTION: This plaster is obtained by laminating a tacky agent layer comprising an acrylic tacky agent onto a polyester film face of a support comprising a laminate of a polyester film and a spun lace nonwoven fabric (e.g. laminate of polyethylene terephthalate film having 7 μm thickness and a polyester nonwoven fabric having 40 g/m&lt;2&gt; weight and manufactured by spun lace method. A medicine (e.g. isosorbide) and an oleic acid alkyl ester (e.g. decyl oleate) are included in an amount of 1-30 wt.% in the above tacky agent layer.
PURPOSE: A composition using CD137 gene is provided to reduce seizure symptom and to prevent apoptosis of nerve cells. CONSTITUTION: A composition for diagnosing brain diseases contains a probe or primer having complementary sequences to a nucleotide sequence of CD137 gene. The brain diseases include epilepsy, seize, Alzheimer&#39;s disease, or Parkinson&#39;s disease. A kit for diagnosing brain diseases contains the probe or primer. A microarray for diagnosing brain diseases contains the primer or probe. A method for screening a material for preventing or treating brain diseases comprises: a step of contacting a sample to cells containing CD137 genes or proteins; a step of measuring CD137 gene and protein expression level or CD137 protein activation level; and a step of determining the sample is a material for treating or preventing brain diseases in case that the CD137 gene and protein expression level or CD137 protein activation level is reduces.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system, a device, a method, and a program for health management capable of presenting efficient and appropriate advice according to a user condition.  &lt;P&gt;SOLUTION: A medical examination interview presenting module 52 periodically presents a medical examination interview to a user terminal 1. An advice selection module 51 selects one of a plurality of advice algorithm registered in an algorithm database 57 on the basis of physiological data, a medical examination interview answer, and a personal set value to present it as an automatic advice to the user terminal 1. The advice selection module 51 asks a doctor terminal 2 for determination if it cannot presents the automatic advice. The doctor terminal 2 presents individual advice to the user terminal 1 via a personal bulletin board of an individual advice module 54. An advice construction module 53 extracts a Q&amp;A history from a Q&amp;A history database 59 to create an advice algorithm.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
1,129,527. Setting hair. L&#39;OREAL. 15 Nov., 1965 [19 Nov., 1964: 16 Feb., 1965], No. 48449/65. Heading DIP. Hair is permanently set by subjecting it while constrained on rollers having a diameter of at least 15 mm to the action of an aqueous composition containing in admixture at least one thiol and at least one .disulphide of a thiol the molar concentration of the disulphide being at least equal to that of the thiol, drying the hair and then removing it from the rollers. The thiol may be thioglycolic acid, thiolactic acid, glycol thioglycolate, glycerol thioglycolate, glycol thiolactate, #-mercaptoethanol, N- carboxymethyl-mercapto-acetamide or thioglycerol and suitable disulphides are those of .these thiols. The disulphide may be produced in situ by oxidation of the thiol with hydrogen peroxide, sodium iodate, sodium periodate or sodium bromate. The composition preferably contains 0.1-10% by weight of the thiol and has pH of 8.5-9.5. It may also contain synthetic resins, e.g. polyvinyl pyrrolidone, or a vinyl pyrrolidone/vinyl acetate copolymer, or polysulphydrylated polymer obtained by the reaction of #-mercaptoethyl-amine with an ethylene/maleic anhydride copolymer, ammonia, urea and ethyl alcohol. The composition may be applied to the hair before or after it is wound up on rollers and allowed to act on the hair for .not more than 30 minutes, the hair then being rinsed, dried and removed from the rollers..Hair may be waved or-straightened by the process.